Imaging characterization of paediatric tumours with the neurotrophic tyrosine receptor kinase fusion transcript.
MRI
cellular congenital mesoblastic nephroma
fusion transcript tumour
infantile fibrosarcoma
neurotrophic tyrosine receptor kinase
Journal
The British journal of radiology
ISSN: 1748-880X
Titre abrégé: Br J Radiol
Pays: England
ID NLM: 0373125
Informations de publication
Date de publication:
28 Mar 2024
28 Mar 2024
Historique:
received:
28
06
2023
revised:
12
12
2023
accepted:
12
01
2024
medline:
1
4
2024
pubmed:
8
2
2024
entrez:
8
2
2024
Statut:
ppublish
Résumé
The neurotrophic tyrosine receptor kinase (NTRK) fusion transcript (FT) is a major genetic landmark of infantile fibrosarcoma (IFS) and cellular congenital mesoblastic nephroma (cCMN) but is also described in other tumours. The recent availability of NTRK-targeted drugs enhances the need for better identification. We aimed to describe the anatomic locations and imaging features of tumours with NTRK-FT in children. Imaging characteristics of NTRK-FT tumours of 41 children (median age: 4 months; 63% <1 year old; range: 0-188) managed between 2001 and 2019 were retrospectively analysed. The tumours were located in the soft tissues (n = 24, including 19 IFS), kidneys (n = 9, including 8 cCMN), central nervous system (CNS) (n = 5), lung (n = 2), and bone (n = 1). The tumours were frequently deep-located (93%) and heterogeneous (71%) with necrotic (53%) or haemorrhagic components (29%). Although inconstant, enlarged intratumoural vessels were a recurrent finding (70%) with an irregular distribution (63%) in the most frequent anatomical locations. Paediatric NTRK-FT tumours mainly occur in infants with very variable histotypes and locations. Rich and irregular intra-tumoural vascularization are recurrent findings. Apart from IFS of soft tissues and cCMN of the kidneys, others NTRK-FT tumours locations have to be known, as CNS tumours. Better knowledge of the imaging characteristics may help guide the pathological and biological identification.
Identifiants
pubmed: 38327010
pii: 7564639
doi: 10.1093/bjr/tqae016
doi:
Substances chimiques
tyrosine receptor
0
Receptors, Amino Acid
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
734-743Subventions
Organisme : Bayer
Organisme : French society for childhood and adolescent cancers and leukemias
Organisme : Imagine for Margo
Informations de copyright
© The Author(s) 2024. Published by Oxford University Press on behalf of the British Institute of Radiology. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Références
Mol Clin Oncol. 2023 Jan 23;18(3):14
pubmed: 36798466
Lancet Oncol. 2018 May;19(5):705-714
pubmed: 29606586
Clin Sarcoma Res. 2020 Aug 06;10:14
pubmed: 32782782
Adv Anat Pathol. 2003 Sep;10(5):243-60
pubmed: 12973047
Radiographics. 2016 Jul-Aug;36(4):1195-214
pubmed: 27399243
Int J Mol Sci. 2020 Jan 23;21(3):
pubmed: 31979374
Neuro Oncol. 2022 Jun 1;24(6):997-1007
pubmed: 34850167
AJNR Am J Neuroradiol. 2019 Apr;40(4):732-736
pubmed: 30846437
J Orthop Sci. 2023 Nov;28(6):1580-1583
pubmed: 35033373
Pediatr Radiol. 2014 Sep;44(9):1124-9
pubmed: 24706181
Pediatr Radiol. 2009 Oct;39(10):1066-74
pubmed: 19629465
Nat Genet. 1998 Feb;18(2):184-7
pubmed: 9462753
Eur J Radiol. 2009 Oct;72(1):30-7
pubmed: 19523781
Histopathology. 1995 Jan;26(1):57-62
pubmed: 7713484
Pathology. 2016 Jan;48(1):47-50
pubmed: 27020209
AJNR Am J Neuroradiol. 2022 Jan;43(1):151-156
pubmed: 34887247
Skeletal Radiol. 1994 Jul;23(5):337-41
pubmed: 7939831
Nat Commun. 2019 Sep 25;10(1):4343
pubmed: 31554817
NPJ Precis Oncol. 2021 Jul 20;5(1):69
pubmed: 34285332